Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-105 in CD5+ relapsed/refractory T-cell lymphoma
NCT06534060Phase 2Recruiting
- Sponsor
- March Biosciences
- Start
- Feb 2025
- Primary completion
- Feb 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of MB-105 in T-cell lymphoma, sponsored by March Biosciences. Started Feb 2025; status: recruiting.
02
Drugs
MB-105
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT06534060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06534060.